hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06329921 id: 232192 briefTitle: Inpatient Monitoring of Unfractionated Heparin overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-04 date: 2026-05 date: 2024-03-26 date: 2024-03-26 name: Vanderbilt University Medical Center class: OTHER briefSummary: Unfractionated heparin (UFH) is the most widely used intravenous (IV) anticoagulant for treating and preventing thromboembolic disease (e.g., blood clots ). UFH must be closely monitored and adjusted in the hospital. There are two assays used to monitor UFH: 1) the activated partial thromboplastin time (PTT) and 2) the chromogenic anti-factor Xa assay (anti-Xa). This study aims to compare PTT and anti-Xa methods for monitoring UFH in a pragmatic, randomized controlled trial to determine which helps patients reach a therapeutic anticoagulation range faster. conditions: Blood Clot conditions: Thrombosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study will be performed as a pragmatic, randomized controlled clinical trial with parallel group assignment. primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 2000 type: ESTIMATED name: PTT protocol name: anti-Xa protocol measure: Time to therapeutic anticoagulation range measure: Measurements in therapeutic anticoagulation range measure: Coagulation laboratory measurements measure: New thrombotic events measure: New clinically relevant bleeding events measure: New coagulation events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Vanderbilt University Medical Center city: Nashville state: Tennessee zip: 37232 country: United States name: Benjamin Tillman, MD role: CONTACT lat: 36.16589 lon: -86.78444 hasResults: False
nctId: NCT06329908 id: TSLG-001 briefTitle: DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs overallStatus: RECRUITING date: 2023-09-27 date: 2024-09-30 date: 2026-10-31 date: 2024-03-26 date: 2024-03-26 name: Zhen-Yu Ding class: OTHER briefSummary: This is a single-center, single-arm, prospective clinical trial to investigate the safety and efficacy of Neo-DCVac combined with ICIs in the treatment of advanced lung cancer resistant to ICIs. conditions: Lung Cancer studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: single arm primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: LG002 measure: The safety of Neo-DCVac combined with ICIs. measure: The efficacy of Neo-DCVac combined with ICIs. measure: The efficacy of Neo-DCVac combined with ICIs. measure: Synergistic anti-tumor mechanism. sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: West China Hospital status: RECRUITING city: Chengdu state: Si Chuan zip: 610000 country: China name: Zhengyu Ding, MD role: CONTACT phone: 18980601957 email: dingzhenyu@scu.edu.cn name: Qing Li, MD role: CONTACT phone: 18702848178 email: liqing@scu.edu.cn lat: 30.66667 lon: 104.06667 hasResults: False
nctId: NCT06329895 id: 22252 briefTitle: A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants overallStatus: RECRUITING date: 2024-03-25 date: 2024-05-23 date: 2024-05-23 date: 2024-03-26 date: 2024-04-19 name: Bayer class: INDUSTRY briefSummary: Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) mutations.
Researchers think that BAY2927088 inhibits drug transporters such as P-gp (P-glycoprotein) and breast cancer resistance protein (BCRP). Drug transporters are proteins that help in the movement of certain drugs into, through, and out of the body's cells. Dabigatran is a drug used in the treatment of blood clots in a vein and rosuvastatin is a drug used in the treatment of high cholesterol in the blood.
An adverse event is any medical problem that a participant has during a study. The study doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment. conditions: Advanced Non-small Cell Lung Cancer conditions: EGFR Mutation conditions: HER2 Mutation conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SEQUENTIAL primaryPurpose: OTHER masking: NONE count: 15 type: ESTIMATED name: BAY2927088 name: Dabigatran etexilate name: Rosuvastatin measure: Cmax of unconjugated dabigatran when given with and without BAY2927088 measure: AUC of unconjugated dabigatran when given with and without BAY2927088 measure: Cmax of rosuvastatin when given with and without BAY2927088 measure: AUC of rosuvastatin when given with and without BAY2927088 measure: Number of participants with treatment-emergent adverse events (TEAEs) measure: Severity of TEAEs sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: PAREXEL International Early Phase Clinical Unit (London) status: RECRUITING city: Harrow zip: HA1 3UJ country: United Kingdom lat: 51.57142 lon: -0.33371 hasResults: False
nctId: NCT06329882 id: 14789 briefTitle: Doxycycline in Type II Diabetes overallStatus: NOT_YET_RECRUITING date: 2024-03-30 date: 2025-03-20 date: 2025-04-20 date: 2024-03-26 date: 2024-03-26 name: Mostafa Bahaa class: OTHER briefSummary: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden conditions: Diabetes Mellitus, Type 2 studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: open label primaryPurpose: TREATMENT masking: NONE maskingDescription: open label count: 60 type: ESTIMATED name: Sitagliptin 100mg name: Doxycyclin measure: Change in glycemic profile measure: Change in glycemic profile sex: ALL minimumAge: 40 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06329869 id: 202401158MIFD briefTitle: Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma acronym: SG-ESCC overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-11 date: 2027-11 date: 2024-03-26 date: 2024-03-26 name: National Taiwan University Hospital class: OTHER name: Gilead Sciences briefSummary: The goal of this clinical trial is to investigate the efficacy and safety of sacituzumab govitecan in patients with advanced esophageal squamous cell carcinoma. conditions: Esophageal Squamous Cell Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 35 type: ESTIMATED name: Sacituzumab govitecan measure: Overall objective response rates (ORR) measure: Overall survival (OS) measure: Progression-free survival (PFS) measure: Duration of response (DOR) measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] measure: Biomarkers-related endpoints sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06329856 id: 202301218RIND briefTitle: Exploring Indications and Practices of Administering Artificial Hydration to Terminal Cancer Patients in Taiwan overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-07 date: 2026-07 date: 2024-03-26 date: 2024-03-26 name: National Taiwan University Hospital class: OTHER briefSummary: Background: The issue of artificial hydration for terminal cancer patients is a classic ethical dilemma in palliative care. It is a common practice especially when patients are incapable of oral intake; however, there is a lack of research on indications and practices for the provision of artificial hydration to terminal cancer patients in Taiwan. The investigators aim to conduct a nationwide survey of palliative care physicians on their indications (general or specific), and practices of providing artificial hydration to terminal cancer patients. With that understanding of reasoning and clinical practice, the investigators would further establish an indigenous, evidence-based consensus guideline to serve as a reference for physicians in Taiwan.
Methods: The study is comprised of two parts. The first part is to conduct a nationwide survey of palliative and oncology care specialists with a questionnaire designed from literature reviews and principles of clinical ethics. After validation of the questionnaire, the investigators will e-mail it to members of the Taiwan Academy of Hospice Palliative Medicine and the Taiwan Society of Cancer Palliative Medicine. The primary outcome measure of the study is the indication and clinical practice of artificial hydration, and the secondary outcome is factors associated with the administration or withdrawal of hydration.
The second part is to establish a national consensus on clinical guidelines for administering artificial hydration, where the investigators will conduct a modified Delphi method for 6 rounds. Literature reviews will be first performed and 14 sessions of one-to-one interviews in Round 1 to develop a draft. Subsequent rounds comprise questionnaire surveys among all panelists, teleconferences and e-mail discussions among core members, and cancer patients/patients' family discussions. Statistical criteria include median and disagreement scores according to the Inter-Percentile Range Adjusted for Symmetry. Items voted for by 70% or more panelists will be selected and formalized into a consensus guideline.
Conclusion: The establishment of a consensus guideline will help clinicians to make an appropriate decision from ethical, medical, cultural, and emotional factors and facilitate cancer patients to achieve a good quality of dying. conditions: Terminal Cancer conditions: Hospice conditions: Palliative Medicine studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: RETROSPECTIVE count: 1270 type: ESTIMATED name: Administering of artificial hydration measure: Likert scale on alteration of administer artificial hydration to the terminal cancer patient and principles of clinical ethics measure: Distributive statistics measure: Disagreement score according to the Interpercentile Range Adjusted for Symmetry (IPRAS) for survey results sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06329843 id: Intermountain briefTitle: Intermountain Inpatient Bilirubin Decision Accuracy Study Using Smartphone-based Measurements by Picterus Jaundice Pro overallStatus: RECRUITING date: 2024-02-12 date: 2024-05 date: 2024-05 date: 2024-03-26 date: 2024-03-26 name: Picterus AS class: INDUSTRY name: Intermountain Medical Center briefSummary: The goal of this project is to evaluate the performance of Picterus Jaundice Pro in an American population, including preterm and term newborns and pre- and post- phototherapy. conditions: Neonatal Jaundice studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 500 type: ESTIMATED name: Picterus Jaundice Pro (JP) measure: Enable high qualitative estimation of bilirubin levels in the blood of term and preterm newborns undergoing phototherapy using Picterus JP. measure: Correlate the bilirubin measurement from Picterus JP with serum bilirubin levels from term-born babies without phototherapy. measure: Correlate the bilirubin measurement from Picterus JP with serum bilirubin levels from preterm-born babies without phototherapy. measure: Correlate the bilirubin measurement from Picterus JP with serum bilirubin levels from term-born babies who have received phototherapy. measure: Correlate the bilirubin measurement from Picterus JP with serum bilirubin levels from preterm-born babies who have received phototherapy. sex: ALL minimumAge: 12 Hours maximumAge: 192 Hours stdAges: CHILD facility: Intermountain Health status: RECRUITING city: Salt Lake City state: Utah zip: 84132 country: United States name: Timothy M Bahr, MS MD role: CONTACT phone: 801-602-6523 email: Tim.Bahr@imail.org name: Kimberlee W Lewis, MS RN role: CONTACT phone: 801.507.7675 email: [kimberlee.weaverlewis@imail.org lat: 40.76078 lon: -111.89105 hasResults: False
nctId: NCT06329830 id: 2023-GAR-001 briefTitle: 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer acronym: LUNAAR overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-05 date: 2028-05 date: 2024-03-26 date: 2024-03-27 name: Rohan Garje class: OTHER name: Janssen Scientific Affairs, LLC briefSummary: The purpose of this research study is to test the safety and possible side effects of Lutetium-177 (177Lu)-Prostate-Specific Membrane Antigen (PSMA)-617 along with niraparib and abiraterone acetate plus prednisone when it is given to people diagnosed with metastatic castration-resistant prostate cancer (prostate cancer that has spread to other parts of the body and does not improve with hormonal therapies) at different dose levels. Once an optimal dose is selected, the researchers want to find out what how well these treatments work to improve survival and control the growth of the tumor. conditions: Metastatic Prostate Cancer conditions: Castration-resistant Prostate Cancer conditions: Metastatic Castration-resistant Prostate Cancer studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: 177Lu-PSMA-617 name: Niraparib abiraterone acetate name: Prednisone measure: Determination of the recommended phase 2 dose (RP2D) measure: Prostatic-specific antigen (PSA)-50 response rate measure: Radiographic progression-free survival (rPFS) measure: Overall survival (OS) measure: PSA-80 response rate measure: Duration of response (DOR) measure: Objective response rate (ORR) sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Miami Cancer Institute city: Miami state: Florida zip: 33176 country: United States name: Rohan Garje, M.D. role: CONTACT phone: 786-596-2000 email: rohan.garje@baptisthealth.net name: Leslie Castaneda role: CONTACT phone: (786) 596-2000 email: leslie.castaneda@baptisthealth.net lat: 25.77427 lon: -80.19366 hasResults: False
nctId: NCT06329817 id: A/28/ER/532/23 briefTitle: Incidence of Regurgitation in Patients Undergoing Intubation in Semi-fowler v/s Supine Position overallStatus: RECRUITING date: 2024-03-15 date: 2024-08 date: 2024-09 date: 2024-03-26 date: 2024-03-26 name: Pak Emirates Military Hospital class: OTHER briefSummary: One of the most dreaded complication of general anaesthesia is aspiration of gastric contents after induction of general anaesthesia.Many endeavours and measures have been practiced to reduce the incidence of aspiration pneumonia.One such method is to intubate the patient in semi-fowler or supine posture.My study is aimed to find out safe and best position between these two after induction of general anaesthesia to prevent aspiration pneumonia. conditions: Inguinal Hernia Bilateral studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: PARTICIPANT count: 100 type: ESTIMATED name: Incidence of regurgitation in two different position. measure: Prevention of aspiration pneumonia sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: PEMH status: RECRUITING city: Rawalpindi state: Punjab zip: 44000 country: Pakistan name: PEMH role: CONTACT phone: +923317055191 email: rabbiafatimasattar555@gmail.com lat: 33.6007 lon: 73.0679 hasResults: False
nctId: NCT06329804 id: RM_01-11-21b briefTitle: The Dose Response Effect of Isometric Handgrip Training Frequency on Blood Pressure in Normotensive Individuals overallStatus: RECRUITING date: 2021-11-01 date: 2024-05-31 date: 2024-05-31 date: 2024-03-26 date: 2024-03-26 name: Swansea University class: OTHER name: National Taiwan Normal University briefSummary: It is estimated by WHO (2021) that 1.4 billion individuals across the globe have high blood pressure with only 14% of people managing these elevated levels. Simple and effective lifestyle strategies are required to help people improve their blood pressure and/or attenuate increases in blood pressure with ageing. Exercise is one possible strategy: in previous research, several different types of exercise have been shown to have effects on blood pressure (Blackwell et al., 2017). However, many individuals do not adhere to currently recommended levels of exercise (150 mins of moderate intensity exercise per week), due to a combination of the required time commitment, lack of motivation, and the associated levels of effort / exertion and discomfort (Korkiakangas et al 2009). Thus, there is a need to investigate alternative exercise interventions which will overcome these barriers but remain effective at improving blood pressure (Herrod, Lund, \& Phillips, 2021).
Low intensity isometric hand grip training (IHGT) has been shown to result in large decreases in rest-ing blood pressure in younger and older age groups, in both men and women, and in individuals with normal as well as elevated baseline blood pressure (Badrov et al, 2013; Bentley et al., 2018; Millar et al., 2014). In this research, IHGT has typically involved performing 4 x 2 IHGT holds at 30% of maximal voluntary contraction, 3 times a week, over a 4-8-week intervention (Millar et al, 2014). Interestingly, there are very few studies that have investigated the effect of changing different protocol parameters on the adaptations in blood pressure, and the minimal effective dose of IHGT is unknown. One important modifiable parameter is training frequency and it is unknown whether reducing the frequency of IHGT will reduce the efficacy for improving blood pressure. Therefore, the aim of this randomised controlled trial is to compare the effect of IHGT with a frequency of 2 or 4 sessions/week on resting blood pressure. conditions: Blood Pressure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 45 type: ESTIMATED name: Isometric Handgrip Exercise Training (IHGT) measure: Resting Systolic Blood Pressure measure: Resting Diastolic Blood Pressure measure: Resting Mean Arterial Blood Pressure measure: Ratings of perceived exertion measure: Affective Valence sex: ALL minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: National Taiwan Normal University status: RECRUITING city: Taipei country: Taiwan name: Yung-Chih Chen, PhD role: CONTACT lat: 25.04776 lon: 121.53185 facility: Swansea University status: RECRUITING city: Swansea country: United Kingdom name: Richard Metcalfe role: CONTACT phone: 01792205678 phoneExt: 4779 email: r.s.metcalfe@swansea.ac.uk lat: 51.62079 lon: -3.94323 hasResults: False
nctId: NCT06329778 id: 50884b briefTitle: Home-Based Child Care Toolkit for Nurturing School-Age Children Study overallStatus: RECRUITING date: 2024-03-15 date: 2024-08-31 date: 2024-10-27 date: 2024-03-26 date: 2024-03-26 name: Mathematica Policy Research, Inc. class: OTHER name: Department of Health and Human Services briefSummary: The goal of this observational study is to build psychometric evidence for the Home-Based Child Care Toolkit for Nurturing School-Age Children (HBCC-NSAC Toolkit) provider questionnaire. The main objectives of the study are to: 1) assess the reliability of the HBCC-NSAC Toolkit provider questionnaire, 2) assess the evidence for its validity compared to other existing measures of HBCC quality, and 3) examine invariance across subgroups (that is, look for the absence of any differential item functioning \[DIF\]). HBCC provider participants will complete a questionnaire in the HBCC-NSAC Toolkit. A subset of providers will also participate in an observation of their child care setting. Parents or guardians of children receiving care from HBCC providers will complete a survey. conditions: Child Development studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 316 type: ESTIMATED measure: The Home-Based Child Care Toolkit for Nurturing School-Age Children provider questionnaire measure: Emlen Scales measure: Multicultural Teaching Competency Scale measure: Family Child Care Program Quality Assessment (FCC PQA) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mathematica Policy Research status: RECRUITING city: Washington state: District of Columbia zip: 20002 country: United States name: Ashley Kopack Klein role: CONTACT phone: 202-484-9220 email: lakopackklein@mathematica-mpr.com lat: 38.89511 lon: -77.03637 hasResults: False
nctId: NCT06329752 id: Not available yet briefTitle: Sciatic Nerve Block for Ankle and Leg Fracture Manipulation in the Emergency Department acronym: AnkleMan overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2025-06 date: 2024-03-26 date: 2024-03-26 name: IRCCS Policlinico S. Matteo class: OTHER briefSummary: The goal of this feasibility clinical trial is to assess the acceptability of ultrasound-guided sciatic nerve block when performed at Emergency Departments for manipulation and temporary stabilization of distal leg and ankle fractures.
* Assess the Adverse Event rate at 48 hours post intervention conditions: Ankle Fractures conditions: Leg Fracture studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Interventional, single-arm, feasibility trial primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Ultrasound-guided Sciatic Nerve block (20 mL of 2% Lidocaine) measure: To assess the technical feasibility of ultrasound-guided sciatic nerve block when performed at Emergency Departments for manipulation and temporary stabilization of distal leg and ankle fractures. measure: Technical success of US-guided sciatic nerve block measure: Analgesic efficacy of US-guided sciatic nerve block measure: Patient-reported and physician-reported satisfaction measure: Safety Endpoint sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Emergency Department, IRCCS Fondazione Policlinico San Matteo city: Pavia zip: 27100 country: Italy name: Santi Di Pietro role: CONTACT phone: 3463153244 email: santi.dipietro@unipv.it lat: 45.19205 lon: 9.15917 hasResults: False
nctId: NCT06329739 id: NeuroPsico_Dopa&PD briefTitle: Genetics in Parkinson's Disease: Behavioral and Cognitive Outcomes overallStatus: RECRUITING date: 2021-12-14 date: 2031-12-14 date: 2031-12-14 date: 2024-03-26 date: 2024-03-26 name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico class: OTHER briefSummary: The genetic landscape of Parkinson's disease (PD) is characterised by rare high penetrance pathogenic variants causing familial disease, genetic risk factor variants driving PD risk in a significant minority in PD cases and high frequency, low penetrance variants, which contribute a small increase of the risk of developing sporadic PD. This knowledge has the potential to have a major impact in the clinical care of people with PD.
Researchers will compare data collected from patients with genetic mutation versus patients without mutation. conditions: Parkinson Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 68 type: ESTIMATED name: Clinical examinations and clinical scales administration measure: Montreal Cognitive Assessment measure: Beck Depression Inventory measure: State-Trait Anxiety Inventory measure: Questionnaire for Impulsive-Compulsive Disorders in Parkinson measure: Pittsburgh Sleep Quality Index measure: Parkinson's Disease Questionnaire-8 measure: Minnesota Multiphasic Personality Inventory 2-RF sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico status: RECRUITING city: Milan zip: 20122 country: Italy name: Francesca Mameli role: CONTACT phone: 0255033621 email: francesca.mameli@policlinico.mi.it lat: 45.46427 lon: 9.18951 hasResults: False